Repro Med Systems, Inc. (KRMD) Misses Q4 EPS by 1c, Revenues Miss

Repro Med Systems, Inc. (NASDAQ: KRMD) reported Q4 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.67 million.

Q4 2020 Financial Highlights:

• Net revenue of $4.1 million
• Gross margin of 57%
• Net loss of $0.8 million

"Like many companies in the healthcare sector, 2020 was a challenging year for KORU Medical," said Jim Beck, Interim Chief Executive Officer. "Despite these challenges, we made progress on many fronts and our employees have remained steadfast in their commitment to improving patients' lives through the use of our specialty infusion solutions. As we move into 2021, our Company remains focused on executing our long-term strategies to drive growth and expand the market for subcutaneous infusions for life-saving therapies. We are excited about our new CEO and are confident that under Linda Tharby's direction, KORU Medical is well positioned for our next phase of growth."

For earnings history and earnings-related data on Repro Med Systems, Inc. (KRMD) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Cingulate posts wider Q2 loss as SG&A spending more than doubles
• Rekor Systems, Inc. (REKR) Tops Q2 EPS by 3c